Diabetes research roundup, May 18–25, 2026

This week's update is narrower than usual. Three new diabetes research papers published May 25 are worth understanding — but none of them change what you should do today. They sit at the basic-science end of the spectrum: researchers investigating why high blood sugar harms specific tissues. Because of a technical failure in this week's data collection, cardiovascular and liver disease sources could not be checked; that gap is explained at the end.

Gestational diabetes: a protective molecule in the placenta

A study published May 25 in Advanced Science identified a protein called Malectin that appears to act as a stress buffer inside placental cells when blood sugar is persistently elevated. 1

Here's the plain-English version: cells have an internal protein-assembly system called the endoplasmic reticulum (ER). When blood glucose stays high for extended periods — as it does in gestational diabetes mellitus (GDM) — this system comes under stress, which can damage placental cells. Researchers (Jiahui Zhu, Yumeng Zhang, Ye Wang, and colleagues) found that Malectin, a protein that normally assists with protein quality control, was present at higher levels in the placental tissue of women with GDM. It appears to protect the placenta's trophoblast cells from the worst of that glucose-driven stress.

This is early-stage research. It doesn't point to a new test or treatment you'd encounter at an OB or endocrinology appointment right now. What it confirms is that controlling blood glucose during pregnancy protects placental function through biological pathways that researchers are still charting — and that there may be future drug targets along this pathway.

What to keep in mind if you're pregnant and managing blood sugar: Your current care — glucose monitoring, dietary adjustments, medication if prescribed — remains the foundation. This kind of basic science work is how the treatments of ten years from now get built. Bring any questions about your GDM management to your OB or endocrinologist at your next visit.

Diabetes and your eyes: the cornea is affected too

Most people with diabetes are told to watch for diabetic retinopathy — damage to blood vessels at the back of the eye. A study published May 25 in International Ophthalmology flags another part of the eye: the corneal endothelium, the thin layer of cells lining the inside front surface of the eye. 2

An optometrist conducts an eye examination using a slit lamp at an eye clinic — Eye exams for people with diabetes cover more than the retina. Photo by Anna Shvets via Pexels

Corneal endothelial cells are normally hexagonal in shape, fitting together like tiles to keep the cornea clear. Researchers (Sharma, Madan, Prasad, and Banerjee) found that chronic high blood glucose disrupts this hexagonal structure — the cells lose their regular geometric arrangement.

Two things make this clinically relevant over the long term. First, these cells don't regenerate once damaged, so protecting them matters. Second, you wouldn't know they were being affected — changes show up on specialized equipment during an eye exam, not through any symptom you'd notice on your own.

This study adds to a growing body of evidence that diabetes affects eye structures beyond the retina, including the cornea at the front. It's one more concrete reason why keeping blood glucose within your target range over years pays off in tissues you might not be thinking about.

Question to raise at your next eye appointment: Ask whether your diabetic eye exam includes assessment of the cornea and anterior structures, in addition to the dilated retinal exam.

Chromium supplements and blood sugar: what a new review actually says

A review paper published May 25 in Biological Trace Element Research (Springer) reframes the science behind chromium(III) — the form of chromium sold as a dietary supplement and sometimes marketed for blood sugar support. 3

Assorted pills and capsules on a marble surface — Chromium supplements are widely available, but the clinical evidence for their use in diabetes remains mixed. Photo by ready made via Pexels

The traditional argument for chromium supplements has been simple: chromium helps insulin work better. The authors — Mehmet Tuzcu, Ramazan Ozmen, Kazim Sahin, and colleagues — argue this framing misses the bigger picture. Their review describes chromium as potentially operating through three biological pathways at once:

Energy sensing in the mitochondria — via a molecule called AMPK, which regulates how cells read and respond to energy availability
Antioxidant defense — via Nrf2 and HO-1 pathways, which protect cells from oxidative damage
Inflammation regulation — via NF-κB, a master switch that controls chronic low-grade inflammation

In plain English: if the authors are right, chromium may do more than nudge insulin signaling. It may also help cells manage the oxidative stress and inflammation that run higher in obesity and type 2 diabetes. The authors explicitly say the field has been stuck in what they call an "ultrainsulinocentric view" and that a broader framework is needed.

Important context for patients: This is a mechanistic review — it describes how chromium might work, not whether chromium supplements improve outcomes in clinical trials. The clinical evidence for chromium supplementation in diabetes management remains mixed, and the American Diabetes Association's standards of care do not currently include a recommendation to take it. Before adding any supplement to your routine, discuss it with your care team. Chromium can interact with diabetes medications and affect blood sugar levels, making that conversation especially important.

Heart and liver updates this week

Due to a technical failure in this week's data collection — affecting access to the American Heart Association, AASLD, and related cardiovascular and liver disease sources — no new cardiovascular or liver updates from May 18–25 could be verified and reported here.

This is a data gap, not a confirmation that nothing new happened in those areas. If you manage a heart or liver condition and have a medical appointment scheduled, it's worth asking your provider directly whether anything relevant came out this week. Cardiovascular and liver disease coverage will resume next week.

These updates are a starting point for conversation with your healthcare provider. Clinical decisions depend on your individual history, medications, and lab results.